Anti-scl-70

Basu, Dhiman; Reveille, John D.

doi:10.1080/08916930400022947

Cited by 52 publications

(33 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ATA is found in about 20% of SSc patients with high disease specificity (97-100% vs healthy controls and other CTDs by immunodiffusion), in about 37% of patients with dcSSc, and in less than 10% of patients with lcSSc [27]. A recent study by Mahler et al [28] confirmed the high specificity of ATA, especially at high titers, determining a prevalence in systemic lupus erythematosus (SLE) of less than 5%.…”

Section: Autoantibodies In Sclerodermamentioning

confidence: 83%

Biomarkers in the Management of Scleroderma: An Update

et al. 2010

View full text Add to dashboard Cite

Scleroderma, or systemic sclerosis, is a clinically heterogeneous disease characterized by fibroproliferative vasculopathy, tissue fibrosis affecting the skin and internal organs, and autoimmune activation. Many biomarker candidates have been identified in the past two decades; however, fully validated measures are still lacking with regard to aiding in the early diagnosis and reflecting the disease activity, severity, prognosis, and response to therapy. An ideal biomarker should be highly sensitive and specific, reflecting the current status of disease; should be related to the disease activity and/or severity in accordance with the clinical evolution; should anticipate clinical changes before they occur; and should add independent information about the risk or prognosis that is reproducible and feasible. This review focuses on the most recent and innovative approaches to identify biomarkers, such as extensive gene expression analysis and proteomics, and on markers and surrogate outcome measures closer to clinical practice, and attempts to evaluate them through the OMERACT (Outcome Measures in Rheumatology Clinical Trials) filter.

show abstract

Section: Autoantibodies In Sclerodermamentioning

confidence: 83%

Biomarkers in the Management of Scleroderma: An Update

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Worsening of prognosis is associated with persistent levels of antibodies [11]. Immunodiffusion, immunoblot, immunoprecipitation, and ELISA assays (with natural or recombinant antigen) are used to detect anti-Scl 70 antibodies [12][13][14][15]. Using a recombinant peptide as antigen has allowed better standardization with consistent results between different laboratories [16].…”

Section: Discussionmentioning

confidence: 99%

Fever of unknown origin secondary to type I crescentic glomerulonephritis and anti-SCl 70 antibodies without clinical manifestations of systemic sclerosis

2008

View full text Add to dashboard Cite

A 57-year-old woman presented with fever and cellulitis of the right leg. Urinalysis and kidney function were normal on admission. Cellulitis remitted but fever persisted for six weeks. X-ray imaging, cultures, serological assays for viruses and autoimmunity did not reveal the cause of fever. Unexpectedly anti-Scl 70 (anti-topoisomerase I) antibodies were positive. A skin biopsy ruled out scleroderma. On the fifth hospitalization week kidney function declined in association with hematuria, leucocyturia, and proteinuria. Prednisone was administered due to clinical suspicion of drug-induced interstitial nephritis. Fever declined in 24 h, but renal failure became rapidly worse requiring hemodialysis. Kidney biopsy revealed extensive crescentic glomerulonephritis (CGN), with much glomerular destruction, with an IgG-positive linear pattern on immunofluorescence microscopy. No overtly active microangiopathy or vasculitis were present. There was no pulmonary involvement and anti-glomerular basement membrane antibodies were not detected in the serum. After one year anti-Scl 70 antibodies were still positive without scleroderma manifestations and 17 months later the patient received a kidney transplant with excellent results. Presentation of type 1 CGN as a fever of unknown origin (FUO) is exceptional. Anti-Scl 70 antibodies are highly specific for scleroderma and are seldom present in other diseases. As far as we are aware there are no published cases of the association of type 1 CGN with anti-Scl 70 antibodies.

show abstract

“…рисунок, б). ДС АТА для ССД высока (97-100%) при срав-нении со здоровым контролем и с пациентами с другими системными воспалительными РЗ при использовании ме-тода ДИД [53]. Специфичность зависит от метода и снижа-ется при использовании ИФА.…”

Section: таблицаunclassified